Carlsmed, Inc. (Ticker: CARL US) is a U.S. medical technology firm that creates personalized solutions for spinal surgery. Using its 'aprevo' technology, the company employs artificial intelligence to design 3D-printed implants tailored to each patient's anatomy, focusing on lower back procedures. Carlsmed is planning its IPO on the NASDAQ Stock Exchange for July 23, 2025. It intends to sell 6.7 million shares to the public, with an initial price estimated between $14.00 and $16.00 per share. This sale is expected to raise about $100.5 million for the company, placing its total market value at approximately $397.7 million. The offering is being managed by BofA Securities, Goldman Sachs, and Piper Sandler.